Stockscreener 앱 받기
5.23
0.19%
0.01
Annexon Inc 주식(ANNX)의 최신 뉴스
Annexon (NASDAQ:ANNX) Shares Down 3.8%Time to Sell? - MarketBeat
HC Wainwright Reaffirms Buy Rating for Annexon (NASDAQ:ANNX) - Defense World
New Data Supports BLA Package - Streetwise Reports
Annexon (NASDAQ:ANNX) Given Buy Rating at HC Wainwright - MarketBeat
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Annexon Awards Major Stock Options Package to New Hires in Strategic Talent Acquisition Move - StockTitan
Annexon shares rise on positive Guillain-Barré study results - Investing.com
Annexon (NASDAQ:ANNX) Shares Gap UpWhat's Next? - MarketBeat
Annexon shares rise on positive Guillain-Barré study results By Investing.com - Investing.com Australia
Annexon Announces Positive Topline Results from Real-World Evidence Study Comparing ANX005 Treatment to Intravenous Immunoglobulin (IVIg) or Plasma Exchange (PE) in a Matched Patient Cohort for the Treatment of Guillain-Barré Syndrome (GBS) - The Manila Times
Annexon Announces Positive Topline Results from Real-World Evidence Study Comparing ANX005 - The Bakersfield Californian
Charles Schwab Investment Management Inc. Boosts Stock Position in Annexon, Inc. (NASDAQ:ANNX) - MarketBeat
The Manufacturers Life Insurance Company Buys 2,450 Shares of Annexon, Inc. (NASDAQ:ANNX) - Defense World
Intech Investment Management LLC Purchases Shares of 26,013 Annexon, Inc. (NASDAQ:ANNX) - Defense World
Annexon, Inc. (NASDAQ:ANNX) Stock Holdings Raised by Fmr LLC - Defense World
Fmr LLC Has $50.69 Million Holdings in Annexon, Inc. (NASDAQ:ANNX) - MarketBeat
Annexon, Inc. (NASDAQ:ANNX) Holdings Lowered by Point72 Asset Management L.P. - MarketBeat
Readystate Asset Management LP Reduces Stake in Annexon, Inc. (NASDAQ:ANNX) - MarketBeat
Annexon to Present Phase 2 ARCHER Data on Protection of - GlobeNewswire
Annexon's ANX007 Shows Breakthrough Vision Protection in Geographic Atrophy Clinical Data - StockTitan
328,698 Shares in Annexon, Inc. (NASDAQ:ANNX) Purchased by Walleye Capital LLC - MarketBeat
Insider Buying: William Carson Acquires Additional Shares of Ann - GuruFocus.com
Annexon director Carson William H. buys $17,056 in stock By Investing.com - Investing.com Nigeria
Annexon director Carson William H. buys $17,056 in stock - Investing.com
Annexon, Inc. (NASDAQ:ANNX) Receives $15.80 Consensus PT from Analysts - MarketBeat
1,433,155 Shares in Annexon, Inc. (NASDAQ:ANNX) Purchased by Sio Capital Management LLC - MarketBeat
Massachusetts Financial Services Co. MA Boosts Holdings in Annexon, Inc. (NASDAQ:ANNX) - MarketBeat
Annexon, Inc. (NASDAQ:ANNX) Shares Bought by GSA Capital Partners LLP - Defense World
Trial results for novel CAD treatment now expected early 2025 - Cold Agglutinin News
The Dodgers’ World Series run brought attention to a rare disease. Annexon is stepping up to the plate. - PharmaVoice
Insiders Enjoy US$903k Return After Buying Annexon Stock - Simply Wall St
HC Wainwright Has Negative View of Annexon FY2027 Earnings - MarketBeat
Annexon (NASDAQ:ANNX) Earns “Buy” Rating from HC Wainwright - Defense World
Annexon (NASDAQ:ANNX) Earns “Overweight” Rating from Cantor Fitzgerald - Defense World
Financial Contrast: Annexon (NASDAQ:ANNX) & Acasti Pharma (NASDAQ:ACST) - Defense World
Annexon, Inc. (NASDAQ:ANNX) Short Interest Down 12.9% in October - MarketBeat
Annexon Grants 495,000 Stock Options to New Employees in Talent Acquisition Push | ANNX Stock News - StockTitan
Annexon's (ANNX) Overweight Rating Reaffirmed at Cantor Fitzgerald - MarketBeat
Annexon's (ANNX) Buy Rating Reiterated at HC Wainwright - MarketBeat
Annexon (NASDAQ:ANNX) Given "Buy" Rating at Needham & Company LLC - MarketBeat
Logos Global Management LP Adjusts Stake in Annexon Inc - GuruFocus.com
Annexon Biosciences Reports Q3 Financial Results - TipRanks
Annexon Inc (ANNX) Quarterly 10-Q Report - Quartzy
Annexon, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Annexon Reports Third Quarter 2024 Portfolio and Financial Results, and Key Anticipated Milestones - GlobeNewswire
Annexon Biosciences to Present at the Jefferies London Healthcare Conference - GlobeNewswire
FMR LLC's Strategic Acquisition of Annexon Inc Shares - GuruFocus.com
Creative Planning Has $206,000 Stake in Annexon, Inc. (NASDAQ:ANNX) - Defense World
Analysts Set Annexon, Inc. (NASDAQ:ANNX) Price Target at $15.80 - MarketBeat
JP Morgan Upgrades Annexon (ANNX) - MSN
Complement Inhibitors Clinical Trial Pipeline Analysis: 40+ - GlobeNewswire
Annexon shares positive on ARCHER trial data, analyst maintains Buy rating - Investing.com
2.88%
2.65%
자본화:
|
볼륨(24시간):